Notable Labs Stock (NASDAQ:NTBL)


RevenueOwnershipFinancialsChart

Previous Close

$0.25

52W Range

$0.10 - $4.24

50D Avg

$0.41

200D Avg

$0.87

Market Cap

$2.39M

Avg Vol (3M)

$2.57M

Beta

-

Div Yield

-

NTBL Company Profile


Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Oct 01, 2014

Website

NTBL Performance


NTBL Financial Summary


Dec 23Dec 22Dec 21
Revenue$310.00K$8.00K$285.00K
Operating Income$-14.66M$-12.92M$-16.91M
Net Income$-11.26M$-14.41M$-16.05M
EBITDA$-19.35M$-12.60M$-16.59M
Basic EPS-$-0.19$-1.80
Diluted EPS-$-0.19$-1.80

Fiscal year ends in Dec 23 | Currency in USD